Introduction
Translocator protein 18 kDa (TSPO) is highly expressed in inflammatory cells, including activated microglia, macrophages, and reactive astrocytes. 1 11 C-PK11195 was the first PET radioligand developed to image TSPO, 2 and its higher affinity enantiomer, 11 C-(R)-PK11195, 3 has successfully imaged areas of inflammation in brain 4 and in the periphery.
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Several second-generation 11 C-labeled radioligands have been developed to increase the specific (i.e. receptor-bound) component of brain uptake; these include 11 C-DAA1106, 6 11 C-PBR28, 7 and 11 C-DPA-713. 8 These second-generation radioligands are widely thought to have greater ''signal to background'' ratio than 11 C-(R)-PK11195, based largely on full-blockade studies in monkeys. As a measure of signal to background, we used binding potential (BP ND ), which is the ratio at equilibrium of specific to nondisplaceable uptake, and found that the BP ND of 11 C-PBR28 9 in brain of rhesus macaques was 70-fold higher than that of 11 C-(R)-PK11195. 10 However, comparable blocking studies for 11 C-(R)-PK11195 have not been performed in human subjects. Instead, the BP ND value for 11 C-(R)-PK11195 in human brain has been indirectly estimated with a pseudo-reference region 11 but never directly measured. Imaging studies conducted with the secondgeneration radioligand 11 C-PBR28 found that the subject's genotype affected the affinity of radioligand binding to TSPO. 12 Specifically, the single nucleotide polymorphism (SNP) rs6971 generates a co-dominantly expressed genotype: homozygous high-affinity binder (HAB), homozygous low-affinity binder (LAB), and heterozygous mixed-affinity binder (MAB). 13 All second-generation radioligands tested to date are sensitive, more or less, to this polymorphism, with an in vitro affinity ratio of HAB to LAB of about 4:1 for DPA-713 and 50:1 for PBR28.
14 However, the sensitivity of 11 C-(R)-PK11195 to this genotype is unclear. Although in vitro receptor binding studies found that 11 C-(R)-PK11195 is insensitive to the genotype, 14 in vivo imaging results are inconsistent among organs. Whole-body imaging studies suggest that the brain is not sensitive to this genotype but that peripheral organs like lung and heart are. 10 However, these results were not based on full quantification using radiometabolitecorrected arterial input function; full quantification might be able to distinguish whether the brain is also sensitive to polymorphism rs6971.
This study sought to directly measure in humans the ''signal to background ratio'' (assessed as BP ND ) of 11 C-(R)-PK11195 using the receptor blocking drug XBD173 15, 16 in humans, and to compare it with one of the most promising second-generation radioligands, 11 C-DPA-713. In previous studies, 11 C-DPA-713 was found to be superior to 11 C-(R)-PK11195 in a rodent model of neuroinflammation 17 and to 11 C-PBR28-a widely used second-generation radioligand-in patients with epilepsy. 18 We compared these two radioligands-11 C-(R)-PK11195 and 11 C-DPA-713-with regard to their sensitivity to polymorphism rs6971 and to their ability to absolutely quantify TSPO in brain as distribution volume (V T ).
Materials and methods

Radiopharmaceutical preparation
11 C-DPA-713 was synthesized as described previously 19 with high radiochemical purity (>99%) and a specific activity of 104 AE 57 GBq/mmol at the time of injection under our Investigational New Drug Application (IND) #116,950.
11 C-(R)-PK11195 was synthesized as previously described 10 with high radiochemical purity (>98%) and specific activity at time of injection of 104 AE 71 GBq/mmol under IND #101,908.
Subjects
This study was approved by the Institutional Review Board of the National Institutes of Health and adhered with the Helsinki Declaration of 1975 (and as revised in 1983); informed consent was obtained from all subjects. Twenty-two healthy volunteers (11 males, 11 females, 32 AE 9 years old) had 11 C-DPA-713 brain PET scans. The distribution of gender and affinity type was 9M/5F HABs, 1M/4F MABs, and 1M/2F LABs. Sixteen healthy volunteers (seven males, nine females, 32 AE 10 years old) had 11 C-(R)-PK11195 scans. The distribution of gender and affinity type was 1M/4F HABs, 4M/4F MABs, and 2M/1F LABs. All subjects were free of current medical or psychiatric illnesses based on medical history, physical examination, electrocardiogram, and laboratory blood and urine tests, which included a complete blood count, serum chemistries, thyroid function test, urinalysis, and urine drug screening. TSPO affinity type was determined by in vitro receptor binding to TSPO on leucocyte membranes or genetic analysis as previously described. 
-(R)-PK11195 in arterial blood
To determine arterial input function for brain PET scans, blood samples (1 mL each) were drawn from the radial artery at 15-s intervals until 2.5 min, followed by samples (3-11 mL) at 3, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75 , and 90 min. The concentration of parent radioligand was measured using high-performance liquid chromatography (HPLC) after separating plasma from whole blood within a few minutes of blood sampling, as previously described. 20 The activity of whole blood was also measured.
Plasma concentration of the parent compound and whole blood activity were fitted to a triexponential function with weighting to minimize the relative distances of the measured values from the fitted values (relative weighting). For one subject who had 11 C-DPA-713 scans with and without XBD173, biexponential fitting was performed because triexponential fitting did not converge. The plasma-free fraction (f P ) was measured by ultrafiltration, as previously described. 21 
Scan procedures
Most PET scans were performed on an Advance Tomograph (GE Healthcare, UK) except three pairs of baseline scans and those after XBD173 administration using 11 C-DPA-713, where a high-resolution research tomograph (HRRT) scanner (CTI, Knoxville, TN, USA) was used. All pairs of baseline and XBD173 blocked scans were performed on the same day. After injection of 11 C-DPA-713 or 11 C-(R)-PK11195 over 1 min, dynamic three-dimensional emission scans were acquired for 90 min. The dynamic data were separated into 27 frames of increasing duration from 30 s to 5 min. One transmission scan using 68 Ge or 137 Cs rod was acquired before radioligand injection. The position of the transmission scan was corrected for motion before applying attenuation correction. PET images were reconstructed with filtered back projection (Hanning filter with 4.0 cut-off) or ordered subset expectation maximization (two iterations and 30 subsets) for Advance Tomograph and HRRT, respectively. After image reconstruction, HRRT data were smoothed with 6.5 mm full-width-half-maximum using a Gaussian filter to match spatial resolution.
XBD173 administration
To induce partial blockade of radioligand binding to TSPO, XBD173 (401.5 g/mol) was administered orally $105 min before injection of the PET ligand.
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XBD173 was administered in six HABs who had 11 C-DPA-713 scans and all 16 subjects who had 11 C-(R)-PK11195 scans. Dosing occurred as follows: for 11 C-DPA-713 scans, 30 mg for three subjects, and 90 mg for three subjects; for 11 C-(R)-PK11195 scans, 45 mg for six subjects, and 90 mg for 10 subjects. We began with a dose of 45 mg for 11 C-(R)-PK11195; our goal was to achieve >50% receptor occupancy to accurately estimate non-displaceable uptake (V ND ). However, because 11 C-(R)-PK11195 scans showed variable receptor occupancy due to low levels of specific binding, we subsequently increased the dose to 90 mg for 11 C-(R)-PK11195. 11 C-DPA-713, which was studied later, showed greater BP ND ; thus, the lowest dose of 30 mg provided measurement of 71-100% receptor occupancy.
Brain image analysis
Image and kinetic analyses for brain PET images were performed using PMOD (version 3.6). All time frames of dynamic PET images were realigned for motion correction. After coregistering PET and a sagittal MR image of 1-mm contiguous slices obtained using a 3.0-T Achieva device (Philips Health Care, Andover, MA, USA), the images were spatially normalized to the MRI template in Montreal Neurological Institute (MNI) space. The PET data in the following volumes of interest (VOI) were obtained in the MNI space: frontal (432 cm 3 Calculating distribution volume with radiometabolite-corrected arterial input function V T is an index of receptor density and equals the ratio at equilibrium of the concentration of radioligand in tissue to that in plasma. The concentration of radioligand in tissue represents the sum of specific binding (receptorbound) and non-displaceable uptake (non-specifically bound and free radioligand in tissue water). 22 Regional V T values were calculated using an unconstrained two-tissue compartment model and Logan plot, 23 using the radiometabolite-corrected plasma input function. For the two-compartment model, brain data for each frame were weighted by assuming that the standard deviation/mean of the data was proportional to the inverse square root of noise equivalent counts; radioactivity in whole blood was used to correct brain data for the vascular component, assumed to be 5% of total brain volume. The delay between the arrival of 11 C-DPA-713 or 11 C-(R)-PK11195 in the radial artery and brain was estimated by fitting the whole brain. For Logan plot, weighting, delay, and consideration of the vascular component were not included as in the standard Logan plot analyses. The one-compartment model was not considered because previous studies had reported the superiority of the two-compartment model for both 11 C-DPA-713 8 and 11 C-(R)-PK11195. 24 Because almost all brain regions express TSPO, we did not apply a reference region method in the kinetic analysis.
Time-stability analysis
To determine the minimal scan length for reliable measurement and to indirectly assess whether 11 C-DPA-713 or 11 C-(R)-PK11195 radiometabolites enter the brain, the time-stability of V T was examined by increasingly truncating the 90-min scan by 5-min increments to the shortest length of 0 to 40 min.
Estimating non-displaceable distribution volume
A modified Lassen plot was used to estimate the specific and non-displaceable components of 11 C-DPA-713 and 11 C-(R)-PK11195 in brain in two ways: (1) with Lassen occupancy plot using the difference in V T at baseline and after partial blockade with XBD173 and (2) with the polymorphism plot ( 11 C-DPA-713 only) using the difference in V T between two affinity types. 15, 25 In general, the Lassen plot enables estimation of V ND as x-intercept by measuring the linear relationship of total uptake (V T ) as x-axis and specific binding (V S ) as y-axis in several brain regions. Here, V S can be substituted with proportional variables:
(1) Lassen occupancy plot: V T at baseline (V T Baseline ) minus V T after partial blockade (V T Block ) for occupancy plot, under the assumption that V ND and the percentage occupancy are the same across all regions
Equation (1) indicates that the slope and x-intercept correspond to receptor occupancy and V ND , respectively. To improve identifiability of V ND for 
Equation (2) estimates both genetic effect (the slope) and a population average for V ND (the x-intercept). The same plot was performed using data from the other pairs of affinity types, i.e. HABs vs. LABs and MABs vs. LABs.
Statistical analysis
The identifiability of V T by the two compartment model was expressed as a percentage and equaled the ratio of the standard error (SE) of V T divided by the value of V T itself. A lower percentage indicates better identifiability. Repeated measures two-way analysis of variance was used to compare V T among different affinity groups by using region as the repeating parameter within subjects. A value of P < 0.05 was considered significant. Linear regression for the modified Lassen occupancy and polymorphism plots was performed using Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). The other statistical analyses were performed with SPSS (version 22 for Windows; SPSS Inc., Chicago, IL, USA). Group data are expressed as mean AE SD.
Results
Pharmacologic effects
No adverse or clinically detectable pharmacologic effects were observed with either 11 C-DPA-713 (28 scans) or 11 C-(R)-PK11195 (32 scans), or in any of the 22 subjects (six and 16 subjects who had 11 C-DPA-713 and 11 C-(R)-PK11195 scans, respectively) who received XBD173. Supplemental Table 1 lists the administered doses of the PET ligands. No significant changes in heart rate, blood pressure, respiratory rate, or ECGs were observed during the PET scan nor in blood or urine test results repeated after the scan.
Kinetic analysis
The brain time-activity curves of 11 C-DPA-713 clearly showed its sensitivity to polymorphism rs6971, whereas 11 C-(R)-PK11195 showed no sensitivity (Figure 1 ). For HABs and MABs, 11 C-DPA-713 showed greater peak radioactivity uptake and slower washout than 11 C-(R)-PK11195, indicating the presence of greater specific binding of this second-generation radioligand. The kinetic analysis of brain and plasma data yielded three major findings. First, the Logan plot gave excellent fitting for all datasets (Supplemental Figure 1 ) and identified V T well for both radioligands. In contrast, an unconstrained two-tissue compartment model failed to identify V T well in some scans. For 11 C-DPA-713, the two-tissue compartment model poorly identified V T (%SE ! 10) or failed to converge in three to nine of the 12 regions in five of 28 scans. For 11 C-(R)-PK11195, the two-tissue compartment model poorly identified V T (%SE ! 10%) in three to seven regions in three of 32 scans. Because the Logan plot can underestimate V T when the data are noisy, we compared it to the two-tissue compartment model in the datasets where the compartment model showed good identifiability of <10% SE. In fact, the Logan plot minimally underestimated V T values: À2.8 AE 11.8% for 11 C-DPA-713 and À0.3 AE 6.0% for 11 C-(R)-PK11195. Thus, because the Logan plot identified V T well in all regions and did not underestimate V T , we used this non-compartmental approach to compare the two radioligands.
The second major finding was that 11 C-DPA-713 showed significant sensitivity to genotype, whereas 11 C-(R)-PK11195 did not. Statistical analysis confirmed that V T for HABs, MABs, and LABs differed significantly for 11 C-DPA-713 (P ¼ 0.001, F ¼ 10.95, df ¼ 2, 19), but not for 11 C-(R)-PK11195 (P ¼ 0.37, F ¼ 1.06, df ¼ 2, 13) ( Table 1) . For example, the whole brain V T of 11 C-DPA-713 in HABs (3.6 AE 0.6 mL cm À3 ) was about 1.9-fold higher than that in MABs (1.9 AE 0.2 mL cm À3 ). The third major finding was that V T for both radioligands was unstable over time-i.e. V T increased with increasing scan duration, consistent with the accumulation of radiometabolites in brain. The most sensitive condition for assessing the presence of radiometabolites is when there is little or low levels of specific receptor binding in brain by the parent radioligand to dilute the impact of radiometabolites. For this reason, we compared the time-stability of the radioligands in LABs and also in HABs after administration of XBD173 ( Figure 2 and Table 2 ). During the last 40 min of the scan of LABs, V T of whole brain increased by 25% for 11 C-DPA-713 and, similarly, by 26% for 11 C-(R)-PK11195. Scans of HABs after XBD173 administration showed a 13% increase for 11 C-DPA-713 and a larger 27% increase for 11 C-(R)-PK11195. Given that 11 C-DPA-713 has greater specific binding than 11 C-(R)-PK11195, this apparent effect of radiometabolites was diminished for 11 C-DPA-713 in HABs ( Figure  2(a) ). That is, during the same time interval, V T of whole brain increased by only 8% for 11 C-DPA-713 but by 26% for 11 C-(R)-PK11195. Estimating specific and non-displaceable uptake C-DPA-713, BP ND was estimated in two ways: by receptor blockade in HABs and by the so-called polymorphism plot, which compares the uptake between two affinity types. 15, 25 After receiving XBD173, all six HABs showed marked blocking effects, both in plasma and in brain (Figure 3) . In plasma, XBD173 significantly increased the concentration of 11 C-DPA-713, consistent with its blocking the distribution of the radioligand to peripheral organs. 10 In brain, receptor blockade increased peak radioactivity uptake (secondary to higher plasma concentrations), increased washout, and decreased total uptake over the 90-min scan. The Lassen occupancy plot of baseline and blocked scans showed an excellent linear regression and determined V ND as 0.44 mL cm À3 with a 95% confidence interval of 0.34-0.53 and receptor occupancy (i.e. slope) of 91 AE 12% (Figure 4(a) ). Based on the estimated V ND (0.44), the ratio of specific to nondisplaceable uptake (i.e. BP ND ) for whole brain was 7.3 AE 2.2, 3.4 AE 0.3, 1.8 AE 0.2 in HABs, MABs, and LABs, respectively. (3) 27% (5) HABs: high-affinity binders; MABs: mixed-affinity binders; LABs: low-affinity binders; V T : total distribution volume.
a % increase of V T in last 40 min.
The polymorphism plot, which was the second method of estimating the BP ND of 11 C-DPA-713, showed excellent fit for all three combinations of the genotypes ( Figure 5 ). V ND and its 95% confidence interval (in parentheses) was 1.21 (0.87-1.56) for HABs-MABs, 0.88 (0.32-1.44) for HABs-LABs, and 0.99 (0.76-1.23) for MABs-LABs. The average (1.03) of these three V ND values from the polymorphism plot was 2.3 times that obtained via the Lassen occupancy plot (0.44). BP ND of whole brain was 2.59 AE 1.32 for HABs, 0.88 AE 0.36 for MABs, and 0.18 AE 0.41 for LABs. Largely because of the higher values of V ND from the polymorphism plot, the BP ND values from the genetic analysis were about one-third those obtained via the Lassen occupancy plot ( Table 1 ). The cause for the different V ND by Lassen occupancy and polymorphism plots is unclear but possibilities are the small sample size and intersubject variability in V ND , including possible differences among different affinity types. For 11 C-(R)-PK11195, BP ND was estimated with only receptor blockade because 11 C-(R)-PK11195 showed no significant sensitivity to genotype (Table 1) . 11 C-(R)-PK11195 showed relatively small blocking effects from XBD173, both in plasma and brain (Figure 3) , consistent with 11 C-DPA-713 having greater specific binding in brain and periphery. The Lassen occupancy plot of baseline and blocked scans determined V ND well as 0.42 (95% C.I.: 0.31-0.53) and 0.39 mL cm À3 (95% C.I.: 0.28-0.51) for HABs and MABs, respectively (Figure 4(b) and (c) ). However, this good identifiability of V ND was achieved only by constraining V ND to be equal among HABs (Figure 4(b) ) or MABs (Figure 4(c) ) because of noisy data due to low specific binding in baseline scans. Receptor occupancy was 31% AE 29% in HABs and 23% AE 18% in MABs. Using V ND values from these Lassen occupancy plots (0.42 for HABs and 0.39 for MABs), we calculated that the ratio of specific to nondisplaceable BP ND for whole brain was 0.75 AE 0.32 in five HABs and 0.89 AE 0.40 in MABs. Because XBD173 binding is affected by the rs6971 SNP, 26 the three LABs who received XBD173 showed no measurable binding blockade. When using the average V ND in HABs and MABs, BP ND in whole brain in LABs was 0.48 AE 0.44.
Because only free ligand enters the brain, V T /f P theoretically reflects receptor binding more accurately than V T, although the additional measurement of f P may decrease precision. XBD173 might have slightly altered f P for both 11 C-DPA-713 and 11 C-(R)-PK11195 (Supplemental Table 2 ). Therefore, Lassen occupancy plots were performed using V T /f P . For 11 C-DPA-713, both occupancy (Supplemental Figure 2(a) ) and polymorphism (Supplemental Figure 3) plots showed a linear regression with high R 2 and narrow confidence intervals for x-intercept, which were similar to the plots obtained using V T . For occupancy plot, BP ND was similar regardless of whether V T /f P or V T was used: 7.4 for HABs using V T /f P (Supplemental Table 3 ) vs. 7.3 using V T ( Table 2 ). The polymorphism plot using V T /f P yielded a BP ND of 3.9 for HABs vs. 2.6 using V T . For 11 C-(R)-PK11195, the occupancy plot obtained using V T /f P provided a good linear regression with high R 2 and a narrow confidence interval for HABs (Supplemental Figure 2(b) ) but not for MABs (Supplemental Figure 2(c) ). One MAB showed a paradoxical 55% increase in V T /f P after binding blockade, but this may have been due to f P measurement errors; occupancy plot was therefore performed after eliminating this subject (Supplemental Figure 2(d) ). The occupancy plots for HABs (Supplemental Figure 2(b) ) and MABs (Supplemental Figure 2(d) ) yielded V ND /f P of 54 and 44 for HABs and MABs, respectively. BP ND for HABs was 1.3 (Supplemental Table 3 ), which was greater than the 0.75 obtained using V T (Table 1) .
Discussion
11 C-DPA-713 was markedly superior to 11 C-(R)-PK11195 for quantifying TSPO in healthy human brain. With regard to perhaps the single most important comparison, the BP ND (signal to background ratio) of HABs for 11 C-DPA-713 was about 10 times greater than that for 11 C-(R)-PK11195. Comparing the accumulation of radiometabolites in brain was more complicated. In LABs (who are most sensitive to radiometabolites in brain), both radioligands had similar time instability of V T during the last 40 min of the scan. However, in HABs and MABs (which comprise roughly 95% of our subjects screened to date), 11 C-DPA-713 showed better time stability of V T than 11 C-(R)-PK11195. This differential effect of genotype was expected, as 11 C-DPA-713 has much greater specific binding of parent radioligand, which dilutes the effects of radiometabolites. Furthermore, because of its much greater BP ND , 11 C-DPA-713 should be more sensitive than 11 C-(R)-PK11195 for detecting small changes in TSPO.
Sensitivity to genotype
11 C-DPA-713 showed a clear sensitivity to genotype. Specifically, V T (mL cm À3 ) was highest in HABs (3.61), then MABs (1.94), then LABs (1.21), and V ND was estimated by occupancy plot to be 0.44. In contrast, no statistically significant differences between the three genotypes were observed with 11 C-(R)-PK11195, indicating that in vivo 11 C-(R)-PK11195 binding in brain is insensitive to genotype. However, the observed insensitivity must be interpreted with caution for several reasons. First, the sample sizes in this study may have been too small to detect a minor sensitivity. Second, because the ''signal to background'' ratio of 11 C-(R)-PK11195 was quite small (BP ND ¼ 0.75), and because brain uptake was low (peaking at only 1.5 SUV), the PET data may have lacked the sensitivity to detect an existing genotype effect. In fact, the noise associated with 11 C-(R)-PK11195 was evident in other measurements. For example, the scatter associated with the occupancy plot was greater for 11 C-(R)-PK11195 than for 11 C-DPA-713 ( Figure 4) . While the present study found no sensitivity to genotype of 11 C-(R)-PK11195 in brain, we previously reported substantial sensitivity of this radioligand in several peripheral organs, including lung, spleen, and kidney. 10 Although genetic sensitivity may vary among organs, a more conservative interpretation is that the radioligand's high non-specific uptake (i.e. low specific binding) in brain obscured a sensitivity that actually exists and would be detected in a much larger sample size. That is, only organs with a very strong specific signal, like lung, spleen, and kidney, are able to detect the genetic effect in small sample sizes.
Instability of receptor measurements over time
Under tracer concentrations of radioligand, V T is described by the following formula.
Because receptor density (B max ) and the affinity (1/ K D ) of the radioligand for the receptor occur independently of time (i.e. are not expected to change during the course of a 90-min scan), V T should also not depend on time if V ND is independent of time. However, because of noise in the PET and plasma data, a minimal number of time points are required to identify V T , which should then be stable using the remainder of the data. However, we found that V T of both 11 C-(R)-PK11195 and 11 C-DPA-713 increased with increased scan duration, showing that the input of parent radioligand itself could not explain brain uptake. For example, V T in LABs for both radioligands increased by about 25% during the last 40 minutes of the scan (Figure 2) . One common cause of time instability is the accumulation of radiometabolites in brain, which would not be explained by an input function of only the parent radioligand. Thus, comparisons of V T between individuals or groups might be secondary to differences in the metabolism of the radioligand and not the density of receptors in brain. Thus, caution should be used when either of these radioligands is used to measure TSPO in LABs. The very high specific binding of 11 C-DPA-713 obviates this concern for HABs and MABs, as potential radiometabolites are such a small percentage of total brain uptake. For example, the V T of 11 C-DPA-713 in HABs increased by only 8% during the last 40 min of the scan.
Conclusion
11 C-DPA-713 was markedly superior to 11 C-(R)-PK11195 for quantifying TSPO in healthy human brain. The BP ND value (''signal to background'') of 11 C-DPA-713 was 10 times that of 11 C-(R)-PK11195 in HABs. The very low specific binding of 11 C-(R)-PK11195 in brain (BP ND ¼ 0.75) may explain why its sensitivity to genotype has only been detected in peripheral organs, like lung, that have much higher density of TSPO than that in brain. 10 Although the high specific binding of 11 C-DPA-713 suggests it is an ideal ligand to measure TSPO, we also found that its V T increased over time, consistent with the accumulation of radiometabolites in brain. Although this putative accumulation of radiometabolites is a small percentage of brain uptake in HABs and MABs, it is a significant problem for LABs, who may need to be excluded from clinical studies.
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